Theraclion

Theraclion FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Theraclion (ALTHE.PA) as of Nov 4, 2026 is 125.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 52.34 % — a change of 140.40% (higher).

FCF Conversion

125.82 %

YoY

140.40%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Theraclion is 2025 125.82 % . FCF Conversion Rate (FCF/EBITDA) of Theraclion was 2024 52.34 % . It decreases by 140.40% higher compared to the previous year.

The Theraclion FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
79.65 EUR
Jan 1, 2019
100.87 EUR
Jan 1, 2020
88.47 EUR
Jan 1, 2021
107.23 EUR
Jan 1, 2022
112.58 EUR
Jan 1, 2023
70.67 EUR
Jan 1, 2024
52.34 EUR
Jan 1, 2025
125.82 EUR
The Theraclion FCF Conversion history
YEARFCF ConversionYoY
125.82 %+140.40%
52.34 %-25.94%
70.67 %-37.23%
112.58 %+4.98%
107.23 %+21.21%
88.47 %-12.29%
100.87 %+26.63%
79.65 %-28.87%
111.99 %-10.28%
124.82 %+36.94%
91.15 %-25.52%
122.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Theraclion Stock analysis

What does Theraclion do? Theraclion SA is a French medical company specializing in the development and production of innovative therapy systems. The company was founded in 2004 and is headquartered in Malakoff, France. Theraclion's business model is based on the development and marketing of medical devices based on High Intensity Focused Ultrasound (HIFU) technology. This technology uses ultrasound pulses to treat targeted areas in the body without the need for surgical intervention. Theraclion specializes in three main areas: oncology, dermatology, and aesthetics. In the field of oncology, Theraclion has developed the Echopulse system, which is used for the treatment of breast tumors. The system applies high-intensity ultrasound pulses to kill tumor cells without damaging surrounding tissue. This non-invasive method of tumor treatment is very promising and has already shown promising results in several studies. In the field of dermatology, Theraclion has developed the Echovist system, which is used for the treatment of nevi (moles). The system also utilizes HIFU technology to destroy the nevi, resulting in a significant improvement in the aesthetic appearance of the skin. In the field of aesthetics, Theraclion has developed the Sonovein system, which is used for the treatment of varicose veins. The system also utilizes HIFU technology to close the veins and thus improve the patient's appearance and quality of life. Theraclion has experienced impressive growth in recent years and is now an important player in the medical industry. The company has filed several patents and works closely with leading doctors and research institutions to maximize the effectiveness of its products. Overall, Theraclion aims to offer innovative therapies that meet the needs of patients and help them lead fulfilling lives. The company is committed to continuously improving its products and services and strives to achieve even greater successes in the future. Theraclion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Theraclion stock

FCF Conversion Rate (FCF/EBITDA) of Theraclion is 125.82 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Theraclion changed from 52.34 % to 125.82 %, representing a 140.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Theraclion since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Theraclion with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Theraclion

All Key Metrics — Theraclion